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ABSTRACT
Hyaluronan has been identified as a ligand for key receptors
related to cancer cell growth and metastasis, such as CD44 and
RHAMM (Misra et al. 2015). Analogs of cysteine deleted tachyplesin
(CDT), an antimicrobial peptide, have shown effective anti-cancer
properties against the A549 cancer cell line (Evans et al. 2016). It
was hypothesized that the hyaluronan binding sequence could act
as a coordination mechanism for the anti-cancer peptide contained
within CDT. To enhance the efficacy of CDT, a shorter peptide
analog was synthesized that contained only the sequence of the
identified hyaluronan binding sequence (HA-CDT) and was tested
on the A549 lung cancer cell line. In addition, two other shortened
CDT analogs were synthesized and tested in both L- and D- forms.
These experiments helped to determine which amino acids in the
sequence contributed to the membranolytic process in the anticancer mechanism of CDT. HA-CDT exhibited reduced anti-cancer
activity relative to CDT in both the D- and the L- form, while the
longer analogs retained some activity. These results allow us to
conclude that one or more key amino acids that are necessary for
anti-cancer activity were removed from CDT in HA-CDT, and the
hyaluronan sequence alone is too short for activity.
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INTRODUCTION
Cysteine Deleted Tachyplesin as an Anti-cancer Peptide
Tachyplesin is derived from the hemocytes of the
Japanese horseshoe crab, Tachypleus tridentatus. Cysteine
deleted tachyplesin (CDT) is a linear analog of Tachyplesin
with the cysteine residues removed (Ramamoorthy et al. 2008;
Wood et al. 2014). Removing the cysteine residues increases the
antimicrobial activity (Ramamoorthy et al. 2008). CDT has been
identified as an antimicrobial peptide and shows activity against
both gram-positive and gram-negative bacteria (Ramamoorthy
et al. 2008). In research conducted by Evans et al. (2016), it
was determined that the D-form of CDT exhibits anti-cancer
properties against A549 cancer cells. To analyze the efficacy
of these anti-cancer properties, D-amino acid CDT analogs
were synthesized via solid phase peptide synthesis and applied
to the cells in a 96 well plate across a serial dilution (Evans
et al., 2016). The efficiency of the peptide was determined by
conducting an MTT assay. The IC50 of D-CDT against A549 was
determined to be 9.8 μM (Evans et al., 2016). The IC50 of L-CDT
against A549 was determined to be greater than 5,000 µM.
Their results suggest that the D-CDT demonstrated far more
activity than L-CDT. In experiments conducted by Evans et
al. (2016), the mechanism by which CDT, specifically D-CDT,
caused cell death in the A549 cancer cells was examined. They
concluded that apoptosis and the ERK1/2 pathways were not
involved in the mechanism by which CDT was exhibiting anticancer effects. In one experiment, they found that D-CDT
acted through a hyaluronan dependent mechanism. They
determined this in their experiments by pre-dosing A549
cells with hyaluronidase, which destroys hyaluronan, which
decreased the cytotoxic effect of the D-CDT and increased the
IC50 (Evans et al., 2016).
Hyaluronan as a Ligand and Membrane Interactions
Hyaluronan is a repeating disaccharide of glucuronic
acid and N-acetyl glucosamine (Laurent and Fraser 1992).
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Hyaluronan has been identified as a ligand for receptors CD44
and RHAMM. CD44 is a glycoprotein receptor located on the
cell surface (Waugh et al. 2009). The RHAMM receptor signals
for the acid-mediated mobility of hyaluronan (Turley et al.
2001). In a general cancer cell, CD44 has been found to be
responsible for adhesion to other cells and substituents in the
extracellular matrix (Waugh et al. 2009). Hyaluronan in different
molecular weights has been found to exhibit different effects on
the cancer cell. Native hyaluronan (nHA), composed of high
molecular weight hyaluronan, is defined as having a molecular
weight of 107 Da (Yang et al. 2012), while oligomer hyaluronan
(oHA) or low molecular weight hyaluronan is defined as having
3-10 disaccharides (Slevin et al. 2007). Low molecular weight
hyaluronan has shown the ability to initiate gene transcription
linked to cell proliferation and migration (Turley et al., 2001).
In a study conducted by Yang et al. (2012), it was determined
that the nHA stimulated the cell surface CD44 clustering using
HK-2 and BT-549 cells; however, oHA could compete with the
same binding sites of nHA on CD44.
Turley et al. (2016) proposed that tumor cells must
have the ability to fragment and metabolize HA in order to
metastasize This fragmentation is how nHA degrades to form
oHA. nHA is produced and sent through the plasma membrane
to be “captured” by the HA receptors, before being degraded
through various pathways (Turley et al., 2016).
A binding motif of interest for RHAMM and CD44
is the B(X7)B binding motif where B is any basic amino acid
(Yang et al., 1994). This is classified as the hyaluronan binding
site. By cross-referencing previous research, Yang et al. (1994)
were able to substantiate that the B(X7)B binding motif was
present in multiple binding regions in CD44, RHAMM, and
the link protein. When hyaluronan binds to the B(X7)B motif
of a peptide, it may be prevented from binding to CD44 on the
surface of the cancer cell. The peptide may then keep hyaluronan
from activating signaling pathways inside the cell that promote
growth, ultimately stopping cancer cell proliferation. The
purpose of this work was to examine whether the B(X7)B motif
in CDT was important and adequate for its anti-cancer activity
as judged by the MTT assay.
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METHODS
Peptide Synthesis
The peptide analogs were synthesized using solid phase peptide
synthesis (SPPS) techniques with N-α-fluorenylmethyloxycarbonyl
(Fmoc) protected amino acids from Anaspec (Freemont, CA). Peptides
were prepared using a PS3 Automated Peptide Synthesizer from
Protein Technologies (Tuscon, AZ). The HBTU (2-(1H-benzotriazol1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate) coupling
agent and Rink amide p-methylbenzhydrylamine (MBHA) resin
were purchased from Bachem Americas, Inc. (Torrance, CA). The
SPPS cycle is summarized in Figure 1. Solvents and deprotecting
agents were obtained from Fisher Scientific (Pittsburgh, PA) and
Sigma-Aldrich Chemical Co. (St. Louis, MO). The peptide product
was separated from the resin, deprotected by treatment with 90%
trifluoroacetic acid (TFA)/10% scavenger cocktail (phenol, water, and
triisopropylsilane, 5:5:2), and cooled to 0˚C. The solution was then
mixed for 2 hours and allowed to come to room temperature. The
peptide was then precipitated using diethyl ether, filtered, re-dissolved
in 30 % acetonitrile/70 % water, and lyophilized.

Figure 1. Visual representation of solid phase peptide synthesis.
Fmoc-protected amino acids are added to the flask, activated, and coupled. Flask contents
are deprotected in preparation for the addition of the next amino acid. When peptide is
complete, after the final coupling, the peptide is cleaved from the resin.
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Purification
The peptide was purified using reverse-phase high
performance liquid chromatography (RP-HPLC), using a Waters
(Milford, MA) instrument with a Phenomenex (Torrance, CA)
Jupiter C18 column (2.2 x 25.0 cm in dimension, flow rate of 10
mL/min). A linear gradient of 10% acetonitrile to 50% acetonitrile
was used for purification. Paper spray mass spectrometry was
used to confirm the molecular weights of the peptides.
Cell Culture
Peptides were tested on A549 adenocarcinoma human
alveolar basal epithelial cells in a biosafety level 2 environment.
The cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) from GE Healthcare (Chicago, IL). Cells were diluted
to a 1:7 ratio of cells to media when cells were 80-95% confluent
in a T-17 flask (2.2 - 2.7 million cells). A549 cells were seeded in
a 96 well plate (200μL per well; 55,000 to 67,500 cells per well).
After 48 hours of growth, the media was removed, the wells were
rinsed with PBS, and the cells were treated with the peptide.
The peptide treatment of 1 mg/mL was serial diluted across
the experimental and negative control rows of the 96 well plate
(Figure 2).
MTT Assay
After 24 hours of peptide treatment, 20μL of 5mg/ml
MTT/PBS solution was added to each well, wrapped in foil, and
incubated. MTT was purchased from Sigma Aldrich (St. Louis,
MO). After 4 hours, the solution was removed from each well, and
100μL of DMSO (dimethyl sulfoxide) was added to each well. The
plate was read using a Biotek Synergy Multimode Detection Plate
Reader, using Gen5 software (Biotek Instruments, Winooski,
VT). The plate was shaken for 5 minutes, and the absorbance of
each well was recorded at 570 nm.
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Figure 2. Peptide dosing of experimental peptide prepared in triplicate with positive
and negative control in a 96 well plate Row A: A549 cells and DMEM cell media, Rows
B-D: A549 cells and peptide treatment (serial dilution across the row), Row E: no cells and
peptide treatment (serial dilution across the row).

Liposome Dye Leakage Assay
Liposomes were prepared by weighing 5 mg of
70:30
palmitoyloleoylphosphatidylcholine
(POPC)/
palmitoyloleoylphosphatidylglycerol (POPG) and dissolving
them in 1 mL of chloroform. This formed zwitterionic
liposomes that mimic the cancer cell membrane. Lipids were
then lyophilized overnight. Then, 0.5 mL of a 30 mM solution of
carboxyfluorescein fluorescent dye (5.64 mg of carboxyfluorescein
dissolved in 0.5 ml of sodium phosphate buffer at pH 7.5) was
added, and the mixture was incubated for 1 hour at room
temperature. To force the lipid to form vesicles with fluorescent
dye encapsulated, lipids were frozen and thawed 5 times using a
dry ice and acetone bath. Prepared liposomes/vesicles were passed
through the extruder 21 times to change the vesicles to 0.2 micron
in size. The resulting dye-encapsulated vesicles were passed
through a Sephadex size exclusion column packed with G-50 gel
beads and saturated with sodium phosphate buffer, to separate the
lipids from the free dye. The vesicles were collected and used for
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the assay. Two control solutions were used for this assay; a buffer
control to represent 0% leakage and a detergent solution to
represent 100% dye leakage (positive control). The detergent used
was 10% Triton X-100. The liposome dye leakage assay was only
conducted on HA-CDT (L). The HA-CDT (L) solution was made
by first dissolving 0.7 mg of peptide in 80 µL DMSO, diluted to 800
µL with buffer. The assay tube composition is given in Table 1.
Biotek’s FLx800 Fluorescence Microplate Reader (Biotek
Instruments, Winooski, VT) was set to excitation of 485 nm and
emission of 528 nm. Solutions were placed in a 96 well plate and
read using the KC4 PC software program (Biotek Instruments,
Winooski, VT).
Solution

Buffer (µL)

Vesicles (µL)

DMSO (µL)

Detergent
(µL)

Control

1480

20

0

0

100% dye leakage

1340

20

50

80

HA-CDT (L)

1438

20

0

0

Table 1. Solution components for Liposome Assay.

RESULTS
Anti-cancer Activity of CDT Analogs
Six CDT analogs were designed, with sequences given
in Table 2. The first four analogs are D- and L- versions of CDT
truncated by one or two arginine residues from the C-terminus.
These were previously found to retain antimicrobial activity and
have enhanced selectivity (Wood et al. 2014). The des-R-CDT
analogs retain the B(X7)B motif, while the des-RR analogs do not.
The HA-CDT analogs contain only the hyaluronan binding motif
and were not tested previously for antimicrobial activity. None of
the analogs had been tested previously for anti-cancer activity.
CDT analogs were tested against A549, adenocarcinoma human
alveolar basal epithelial cells, to determine the relative anti-cancer
activity. This was done to determine whether the amino acids in
the B(X7)B motif play a key role in the anti-cancer activity of the
peptides and whether that is sufficient for activity. The IC50 (the
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half maximal inhibitory concentration) of the CDT peptide analogs
of interest decreased (meaning they became better) as the peptide
was truncated from the C-terminus; however, upon truncating
the peptide to only the hyaluronan binding sequence, there was no
longer much anti-cancer activity present (Figures 3-5 and Table 2). In
addition to these trends, the D-amino acid analogs presented better
efficacy than the L-amino acid analogs. The IC50 of the L- form of desR-CDT was 190.5 µM, and the D-form was 52.5 µM (Figure 3). The
IC50 of the L-form of des-RR-CDT was 97.7 µM, and the D-form was
38.01 µM (Figure 4). The IC50 of the D-form of des-RR-CDT was the
lowest reported of this study, meaning that this analog had the best
anti-cancer activity. The IC50 of both the L-form of HA-CDT and the
D-form was > 800 µM (Figure 5). The data, along with the molecular
weights of the peptides, has been condensed into Table 2.
Liposome Dye Leakage
A liposome dye leakage assay was conducted on HA-CDT
to allow for comparison to results for the other CDT analogs that
have been previously published by Wood et al. (2014). This assay is
based on the ability of the peptides to break open a dye-encapsulating
liposome and is used as a model for membrane damage. There is an
increase in fluorescence if the liposome is disrupted and dye leaks out.
The solution containing sodium phosphate buffer and liposomes had
an average fluorescence emittance at 528 nm of 24.25 (Table 3). The
positive control detergent solution represents 100% dye leakage since
the detergent breaks the vesicles open. The detergent solution had an
average fluorescence emittance at 528 nm of 30 (Table 3). The L-amino
acid HA-CDT peptide had an average fluorescence emittance at 528
nm of 26 (Table 3). Results can be used to determine if the HA-CDT
peptide can cause cell membrane disruption.
The percent liposome leakage was calculated using the
equation:

The percent dye leakage of the L-amino acid form of HA-CDT was
calculated to be 30.4%.
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Solution

1

2

4

Average Fluorescence value

Buffer

23

25

25

24.25

Detergent

30

30

31

30

Peptide: HA-CDT (L)

25

27

26

26

Table 2. Peptide analog sequences, molecular weights, and resulting IC50 values.
Portions of B(X7)B shown in bold; * denotes inactivity at maximum concentration tested

Peptide

Sequence

Mol. Weight (g/mol) IC50 (μM)

L-des-R-CDT

KWFRVYRGIYRR

1699

190.5

D-des-R-CDT

kwfrvyrgiyrr

1699

52.5

L-des-RR-CDT

KWFRVYRGIYR

1543

97.7

D-des-RR-CDT

kwfrvyrgiyr

1543

38.01

L-HA-CDT

RVYRGIYR

1237

>800

D-HA-CDT

rvyrgiyr

1237

>800

Table 3. Negative control, positive control, and experimental solutions for Liposome
Dye Leakage. The buffer (negative control) represented 0% dye leakage. The detergent
(positive control) represented 100% dye leakage. The L-amino acid peptide HA-CDT was
tested for dye leakage against liposomes to replicate the membrane of the cancer cell.

Figure 3. The percent viability (100%=1) of des R CDT D- and L- analogs against A549
cells. The IC50 of the L-and D- configurations were 190.5 μM and 52.5 μM, respectively.
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Figure 4. The percent viability (100%=1) of des-RR-CDT D- and L- analogs against
A549 cells. IC50 of the L- and D- configurations were 97.7 μM and 38.01 μM, respectively.

DISCUSSION
Surprisingly, the des-RR-CDT analogs that are missing
one amino acid from the B(X7)B motif for hyaluronan binding still
retained anti-cancer activity. In fact, the shorter analog had slightly
better cytotoxic effects against A549 cells. This was an unexpected
finding since previous results indicated that the activity of D-CDT
was hyaluronan-mediated. A different mechanism may be at play
for these shorter analogs. In addition, the hyaluronan binding motif
itself is not enough for activity.
The liposome dye assay revealed information about the
anti-cancer mechanism of these analogs. The experiment showed
that L-HA-CDT does not have as much membranolytic activity as
the longer analogs do. This result correlates with the inactivity found
when L-HA-CDT and D-HA-CDT were tested against A549 cancer
cells (Table 2). In research conducted by Wood et al. (2014), higher
membranolytic activity was found in the other CDT analogs tested.
Including the results from Wood et al., it can be seen that, as the
CDT sequence was continually truncated, the percent dye leakage
determined by a liposome dye leakage assay decreased (Figure 6).
It should be noted that des-R-CDT and des-RR-CDT demonstrated
significant anti-cancer activity and had relatively high percentages
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of dye leakage (Wood et al. 2014). These results suggest that, for
peptides to demonstrate anti-cancer activity against A549 cells,
membranolytic activity is necessary or at least helpful. The inactivity
of the HA-CDT analogs may be due to the fact that they are too
short to interact properly with the cell membrane or because the
HA-CDT peptide is missing key N-terminal amino acids in its
sequence that are present in other active analogs and that help to
facilitate the necessary interactions to break open the membrane.
Membrane active peptides tend to have both hydrophobic and
positively charged regions, which are important for interaction
(Wood et al. 2014).
CONCLUSION

Figure 5. Percent liposome dye leakage decreases as peptide is truncated. Liposome dye
leakage assay results for L-HA-CDT (red) along with results taken from Wood et al. for
L-CDT, L-des-R-CDT, and L-des-RR-CDT (black).

While HA-CDT analogs containing only the hyaluronan binding
sequence had little to no anti-cancer activity, their inactivity helps us to
determine information about which amino acids play a key role in the
anti-cancer activity of other active CDT peptides. Amino acids at the
N-terminus of the CDT sequence may play a prevalent role in the anticancer activity of CDT analogs. D-des-RR-CDT peptide demonstrated
the highest efficacy and only differed from D-HA-CDT, which lacked
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activity, by three amino acids: lysine, tyrosine, and phenylalanine. While
the hyaluronan binding sequence may not be essential for anti-cancer
activity in these analogs, it appears that membranolytic activity plays a
role. It is possible that the three N-terminal amino acids are important
for influencing the three-dimensional conformation of the peptide and/
or for membrane interaction or disruption.
Future Directions
To confirm the importance of the amino acids starting at the
N-terminus of CDT (lysine, tyrosine, and phenylalanine), additional
analogs could be made with the starting sequence KWFRVYRGIYR and
truncated from the N-terminus one amino acid at a time. The potential
activity would validate the importance of one, two, or all three of the
amino acids in the anti-cancer activity that CDT and its analogs possess.
Binding assays should also be conducted to confirm the presence of
the hyaluronan binding. The synthesis of an additional peptide that
contains two or more units of the hyaluronan binding sequence could
reveal if molecular weight or length is a factor in the efficacy of CDT
analogs against A549 cells. In addition, the active compounds can be
tested against non-cancerous lung cells to determine if they are selective
for cancer cells, a desirable trait for a potential drug treatment.
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